1. Pazos F. Range of adiposity and cardiorenal syndrome. World J Diabetes 2020; 11: 322-350.
2. Konopelniuk VV, Goloborodko II, Ishchuk TV, Synelnyk TB, Ostapchenko LI, Spivak MY, et al. Efficacy of Fenugreek-based bionanocomposite on renal dysfunction and endogenous intoxication in high-calorie diet-induced obesity rat model—comparative study. EPMA J 2017; 8: 377-390.
3. Li XY, Lu SS, Wang HL, Li G, He YF, Liu XY, et al. Effects of the fenugreek extracts on high‐fat diet‐fed and streptozotocin‐induced type 2 diabetic mice. Animal Model Exp Med 2018; 1: 68-73.
4. World Health Organization. Obesity and Overweight. https:// www.who.int/news-room/fact-sheets/detail/obesityand-overweight, 2020.
5. Sharma I, Liao Y, Zheng X, Kanwar YS. New pandemic: Obesity and associated nephropathy. Front Med 2021; 8: 673556-673571.
6. Chenxu G, Xianling D, Qin K, Linfeng H, Yan S, Mingxin X, et al. Fisetin protects against high-fat diet-induced nephropathy by inhibiting inflammation and oxidative stress via the blockage of iRhom2/NF-κB signaling. Int Immunopharmacol 2021; 92: 107353.
7. Noshahr ZS, Salmani H, Khajavi Rad A, Sahebkar A. Animal models of diabetes‐associated renal injury. J Diabetes Res 2020; 2020: 9416419-9416434.
8. Khare P, Jagtap S, Jain Y, Baboota RK, Mangal P, Boparai RK, et al. Cinnamaldehyde supplementation prevents fasting‐induced hyperphagia, lipid accumulation, and inflammation in high‐fat diet‐fed mice. Biofactors 2016; 42: 201-211.
9. Quyamuddin MD, Kumar P, Kumar S, Haque MR. Nephroprotective activity of ethanolic extract of Cinnamomum zeylanicum bark against acetaminophen induced nephrotoxicity in albino rats. J Drug Deliv Ther 2020; 10: 80-86.
10. Quamuddin MD, Kumar S, Kumar P, Iqbal K, Haqu MD. Protective effect of Cinnamomum zeylanicum aqueous extract against paracetamol-induced nephrotoxicity in albino rats. Pharma Innov J 2021; 10: 282-286.
11. Zuo J, Zhao D, Yu N, Fang X, Mu Q, Ma Y, et al. Cinnamaldehyde ameliorates diet-induced obesity in mice by inducing browning of white adipose tissue. Cell Physiol Biochem 2017; 42: 1514-1525.
12. Jain MR, Giri SR, Trivedi C, Bhoi B, Rath A, Vanage G, et al. Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid‐lowering and insulin‐sensitizing effects in preclinical models. Pharmacol Res Perspect 2015; 3: e00136-150.
13. Aref AB, Ahmed OM, Ali LA, Semmler M. Maternal rat diabetes mellitus deleteriously affects insulin sensitivity and Beta‐cell function in the offspring. J Diabetes Res 2013; 2013: 429154-429164.
14. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-474.
15. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25:192-205.
16. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases: The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
17. Loos RJ, Yeo GS. The genetics of obesity: From discovery to biology. Nat Rev Genet 2022; 23: 120-133.
18. García-Carro C, Vergara A, Bermejo S, Azancot MA, Sellarés J, Soler MJ. A nephrologist perspective on obesity: from kidney injury to clinical management. Front Med 2021; 8: 655871-665882.
19. Sandino J, Martín-Taboada M, Medina-Gómez G, Vila-Bedmar R, Morales E. Novel insights in the physiopathology and management of obesity-related kidney disease. Nutrients 2022; 14: 3937-3949.
20. Kreiner FF, Schytz PA, Heerspink HJ, von Scholten BJ, Idorn T. Obesity-related kidney disease: Current understanding and future perspectives. Biomedicines 2023; 11: 2498-2513.
21. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011; 7: 146-57.
22. Zhou Z, Kandhare AD, Kandhare AA, Bodhankar SL. Hesperidin ameliorates bleomycin-induced experimental pulmonary fibrosis via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways. EXCLI J 2019; 18: 723-745.
23. Wang Z, Li X, Chen H, Han L, Ji X, Wang Q, et al. Resveratrol alleviates bleomycin-induced pulmonary fibrosis by suppressing HIF-1α and NF-κB expression. Aging (Albany NY) 2021; 13: 4605-4616.
24. Kandhare AD, Bandyopadhyay D, Thakurdesai PA. Low molecular weight galactomannans-based standardized fenugreek seed extract ameliorates high-fat diet-induced obesity in mice via modulation of FASn, IL-6, leptin, and TRIP-Br2. RSC Adv 2018; 8: 32401-32416.
25. Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, et al. Leptin and obesity: Role and clinical implication. Front Endocrinol 2021; 12: 585887-585901.
26. Jiang L, Wang Q, Yu Y, Zhao F, Huang P, Zeng R, et al. Leptin contributes to the adaptive responses of mice to high-fat diet intake through suppressing the lipogenic pathway. PLoS One 2009; 4: e6884-6893.
27. Chen H, Li LL, Du Y. Krüppel-like factor 15 in liver diseases: Insights into metabolic reprogramming. Front Pharmacol 2023; 14: 1115226-1115237.
28. Flores-Cordero JA, Pérez-Pérez A, Jiménez-Cortegana C, Alba G, Flores-Barragán A, Sánchez-Margalet V. Obesity as a risk factor for dementia and Alzheimer’s disease: The role of leptin. Int J Mol Sci 2022; 23: 5202-5224.
29. Hou J, Xu Y, Sun W, Gao P. Adiponectin and glomerular diseases. Int J Clin Exp Med 2019; 12: 1179-1185.
30. Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab 2014; 28: 71-79.
31. Zhou G, Cui J, Xie S, Wan H, Luo Y, Guo G. Vitexin, a fenugreek glycoside, ameliorated obesity-induced diabetic nephropathy via modulation of NF-κB/IkBα and AMPK/ACC pathways in mice. Biosci Biotechnol Biochem 2021; 85: 1183-1193.
32. Butt L, Unnersjö-Jess D, Höhne M, Edwards A, Binz-Lotter J, Reilly D, et al. A molecular mechanism explaining albuminuria in kidney disease. Nat Metab 2020; 2: 461-474.
33. Kakutani Y, Morioka T, Mori K, Yamazaki Y, Ochi A, Kurajoh M, et al. Albuminuria rather than glomerular filtration rate is associated with vascular endothelial function in patients with type 2 diabetes. J Diabetes Complications 2020; 34: 107702.
34. Kotsis V, Martinez F, Trakatelli C, Redon J. Impact of obesity in kidney diseases. Nutrients 2021; 13: 4482-4498.
35. Verma A, Schmidt IM, Claudel S, Palsson R, Waikar SS, Srivastava A. Association of albuminuria with chronic kidney disease progression in persons with chronic kidney disease and normoalbuminuria: A cohort study. Ann Intern Med 2024; 177: 467-475.
36. Azemi NA, Azemi AK, Abu-Bakar L, Sevakumaran V, Muhammad TS, Ismail N. Effect of linoleic acid on cholesterol levels in a high-fat diet-induced hypercholesterolemia rat model. Metabolites 2022; 13: 53-68.
37. Al-Mansoori L, Al-Jaber H, Prince MS, Elrayess MA. Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance. Inflammation 2022; 1: 1-4.
38. Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, Tagua VG, Hernández-Carballo C, Ferri C, et al. Inflammatory targets in diabetic nephropathy. J Clin Med 2020; 9: 458-481.
39. Taguchi S, Azushima K, Yamaji T, Urate S, Suzuki T, Abe E, et al. Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy. Sci Rep 2021; 11: 23587-23598.
40. Kamianowska M, Kamianowska A, Wasilewska A. Urinary levels of kidney injury molecule-1 (KIM-1) and interleukin-18 (IL-18) in children and adolescents with hyperuricemia. Adv Med Sci 2023; 68: 79-85.
41. Eleazu C, Suleiman JB, Othman ZA, Zakaria Z, Nna VU, Hussain NH, et al. Bee bread attenuates high fat diet induced renal pathology in obese rats via modulation of oxidative stress, downregulation of NF-kB mediated inflammation and Bax signalling. Arch Physiol Biochem 2022; 128: 1088-1104.
42. Lasker S, Rahman MM, Parvez F, Zamila M, Miah P, Nahar K, et al. High-fat diet-induced metabolic syndrome and oxidative stress in obese rats are ameliorated by yogurt supplementation. Sci Rep 2019; 9: 2002620041.
43. Huchzermeyer B, Menghani E, Khardia P, Shilu A. Metabolic pathway of natural antioxidants, antioxidant enzymes and ROS providence. Antioxidants 2022; 11: 761-781.
44. Zhao H, Zhang R, Yan X, Fan K. Superoxide dismutase nanozymes: An emerging star for anti-oxidation. J Mater Chem B 2021; 9: 6939-6957.
45. Pei J, Pan X, Wei G, Hua Y. Research progress of glutathione peroxidase family (GPX) in redoxidation. Front Pharmacol 2023; 14: 1147414-1147428.
46. Pérez-López L, Boronat M, Melián C, Brito-Casillas Y, Wägner AM. Animal models and renal biomarkers of diabetic nephropathy. Adv Exp Med Biol 2021; 4: 521-551.
47. Moresco RN, Bochi GV, Stein CS, De Carvalho JA, Cembranel BM, Bollick YS. Urinary kidney injury molecule-1 in renal disease. Clin Chim Acta 2018; 487: 15-21.
48. Chen S, Chen J, Li S, Guo F, Li A, Wu H, et al. High-fat diet-induced renal proximal tubular inflammatory injury: Emerging risk factor of chronic kidney disease. Front Physiol 2021; 12: 786599-786610.
49. Gluhovschi C, Gluhovschi G, Petrica L, Timar R, Velciov S, Ionita I, et al. Urinary biomarkers in the assessment of early diabetic nephropathy. J Diabetes Res 2016; 2016: 4626125-4626138.
50. Yu Y, Mo H, Zhuo H, Yu C, Liu Y. High fat diet induces kidney injury via stimulating Wnt/β-catenin signaling. Front Med 2022; 9: 851618-851627.
51. Yang S, Cao C, Deng T, Zhou Z. Obesity-related glomerulopathy: A latent change in obesity requiring more attention. Kidney Blood Press Res 2020; 45: 510-522.
52. Reggio S, Rouault C, Poitou C, Bichet JC, Prifti E, Bouillot JL, et al. Increased basement membrane components in adipose tissue during obesity: Links with TGFβ and metabolic phenotypes. J Clin Endocrinol Metab 2016; 101: 2578-2587.
53. Juszczak F, Caron N, Mathew AV, Declèves AE. Critical role for AMPK in metabolic disease-induced chronic kidney disease. Int J Mol Sci 2020; 21: 7994-8017.
54. Sheng H, Zhang D, Zhang J, Zhang Y, Lu Z, Mao W, et al. Kaempferol attenuated diabetic nephropathy by reducing apoptosis and promoting autophagy through AMPK/mTOR pathways. Front Med 2022; 9: 986825-986835.
55. Shen J, Dai Z, Li Y, Zhu H, Zhao L. TLR9 regulates NLRP3 inflammasome activation via the NF-kB signaling pathway in diabetic nephropathy. Diabetol Metab Syndr 2022; 14: 26-38.
)